Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

Table 2 Comparative overview of the primary parameters at inclusion versus end-of-treatment in study groups and in overall patients

	Units	Overall		Group T		Group V
		mean ± SE	P	mean ± SE	P	mean ± SE	P
sBP (V1)	mmHg	156.54 ± 1.28	< 0.0001	155.71 ± 1.61	< 0.0001	157.42 ± 2.04	< 0.0001
sBP (V6)		134.24 ± 1.28		133.21 ± 1.23		135.35 ± 2.31
dBP (V1)	mmHg	101.65 ± 1.05	< 0.0001	101.43 ± 1.17	< 0.0001	101.89 ± 1.8	< 0.0001
dBP (V6)		77.8 ± 1.04		77.14 ± 1.25		78.5 ± 1.7
ALT (V1)	IU/L	67.65 ± 2.01	< 0.001	66.96 ± 2.95	< 0.001	68.38 ± 2.75	< 0.001
ALT (V6)		49.48 ± 1.16		46.68 ± 1.42		52.50 ± 1.70
AST (V1)	IU/L	70.31 ± 2.34	< 0.001	72.78 ± 3.53	< 0.001	67.65 ± 3.02	< 0.001
AST (V6)		51.11 ± 1.83		47.57 ± 2.08		54.92 ± 2.95
GGT (V1)	IU/L	23.85 ± 1.62	NS	22.60 ± 2.37	NS	25.19 ± 2.22	NS
GGT (V6)		21.02 ± 1.98		21.96 ± 3.55		20 ± 1.58
B (V1)	mg/dL	0.89 ± 0.02	NS	0.9 ± 0.03	NS	0.88 ± 0.04	NS
B (V6)		0.94 ± 0.02		0.94 ± 0.03		0.93 ± 0.03
BMI (V1)	kg/m2	27.42 ± 0.36	NS	27.21 ± 0.51	NS	27.65 ± 0.53	NS
BMI (V6)		26.96 ± 0.36		26.93 ± 0.49		27.00 ± 0.54
HOMA-IR (V1)	mg ×&mgr;IU	7.7 ± 0.24	< 0.001	7.81 ± 0.40	< 0.001	7.57 ± 0.25	< 0.05
HOMA-IR (V6)	/dL × 10-2	5.19 ± 0.18		4.48 ± 0.21		5.95 ± 0.22
TG (V1)	mg/dL	161.51 ± 4.98	< 0.051	165.64 ± 6.95	< 0.0311	157.08 ± 7.18	NS1
		F: 168.42 ± 8.28		F: 169.85 ± 11.2		F: 166.75 ± 12.82
		M: 155.10 ± 5.63		M:161.42 ± 8.49		M: 148.78 ± 7.31
TG (V6)		153.96 ± 4.8		154.14 ± 6.79		153.77 ± 6.93
		F: 160 ± 8.29		F: 156.78 ± 11.33		F: 163.75 ± 12.61
		M: 148.35 ± 5.09		M: 151.5 ± 7.88		M: 145.21 ± 6.65
TC (V1)	mg/dL	196.46 ± 1.13	< 0.0081	196.07 ± 1.5	< 0.0241	196.88 ± 1.73	NS1
		F: 191.77 ± 1.5		M: 200.57 ± 1.29		M: 201.07 ± 2.07
		M: 200.82 ± 1.2		F: 191.57 ± 2.13		F: 192 ± 2.19
TC (V6)		194.04 ± 1.19		191.89 ± 1.64		196.35 ± 1.64
		F: 189.73 ± 1.58		F: 188 ± 2.23		F: 191.75 ± 2.19
		M: 198.04 ± 1.39		M: 195.79 ± 1.96		M: 200.29 ± 1.87
NAS (V1)	Point	5.89 ± 0.14	< 0.0011	6 ± 0.18	< 0.0451	5.77 ± 0.22	NS1
Steatosis		2.16 ± 0.09	2Excepting inflammation (V1) vs (V6)	2.21 ± 0.12		2.11 ± 0.16	2Excepting steatosis (V1) vs (V6) P = 0.027
Inflammation		1.70 ± 0.06	NS	1.68 ± 0.09		1.73 ± 0.09
Balooning		2.02 ± 0.1		2.11 ± 0.13		1.92 ± 0.16
NAS (V6)		4.96 ± 0.14		4.57 ± 0.18		5.38 ± 0.2
Steatosis		1.74 ± 0.09		1.71 ± 0.11		1.77 ± 0.15
Inflammation		1.55 ± 0.10		1.32 ± 0.12		1.81 ± 0.14
Balooning		1.67 ± 0.08		1.53 ± 0.11		1.81 ± 0.13
Fibrosis (V1)	Point	2.11 ± 0.11	< 0.001	2.07 ± 0.16	< 0.001	2.15 ± 0.15	NS
Fibrosis (V6)		1.57 ± 0.09		1.32 ± 0.13		1.84 ± 0.11

sBP: Systolic blood pressure; dBP: Diastolic blood pressure; ALT: Alanine-aminotransferase; AST: Aspartate-aminotransferase; GGT: Gamma-glutamyl transpeptidase; B: Bilirubin; BMI: Body mass index; HOMA-IR: Homeostasis model assessment index for insulin-resistance; TG: Triglycerides; TC: Total cholesterol; NAS: NASH activity score; M: Male patients; F: Female patients; V1: Index data at visit 1; V6: End-of-treatment data;

¹For any comparation;

²Exception.